NASDAQ:TVTX Travere Therapeutics (TVTX) Stock Price, News & Analysis $9.89 +0.12 (+1.23%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$9.69▼$10.1250-Day Range$6.16▼$10.2952-Week Range$5.12▼$17.57Volume672,615 shsAverage Volume1.23 million shsMarket Capitalization$752.93 millionP/E RatioN/ADividend YieldN/APrice Target$14.64 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Travere Therapeutics alerts: Email Address Travere Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.58 Rating ScoreUpside/Downside48.0% Upside$14.64 Price TargetShort InterestBearish13.27% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.92) to ($1.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.30 out of 5 starsMedical Sector749th out of 936 stocksPharmaceutical Preparations Industry349th out of 436 stocks 3.3 Analyst's Opinion Consensus RatingTravere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 7 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageTravere Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Travere Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.27% of the outstanding shares of Travere Therapeutics have been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Travere Therapeutics has recently decreased by 2.13%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTravere Therapeutics does not currently pay a dividend.Dividend GrowthTravere Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TVTX. Previous Next 2.5 News and Social Media Coverage News SentimentTravere Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Travere Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for TVTX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows2 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Travere Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.75% of the stock of Travere Therapeutics is held by insiders.Read more about Travere Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Travere Therapeutics are expected to grow in the coming year, from ($3.92) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Travere Therapeutics is -4.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Travere Therapeutics is -4.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTravere Therapeutics has a P/B Ratio of 3.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Travere Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyNvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.To see Porter Stansberry's new AI prediction go here now. About Travere Therapeutics Stock (NASDAQ:TVTX)Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Read More TVTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TVTX Stock News HeadlinesJuly 25 at 4:30 PM | globenewswire.comTravere Therapeutics to Report Second Quarter 2024 Financial ResultsJuly 8, 2024 | globenewswire.comTravere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual ConferenceJuly 26, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.June 11, 2024 | globenewswire.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 16, 2024 | markets.businessinsider.comBuy Rating on Travere Therapeutics: Filspari’s Market Potential and Positive Financial OutlookMay 15, 2024 | globenewswire.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2024 | globenewswire.comTravere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association CongressMay 8, 2024 | finance.yahoo.comLoss-Making Travere Therapeutics, Inc. (NASDAQ:TVTX) Expected To Breakeven In The Medium-TermJuly 26, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.May 8, 2024 | sfgate.comGossamer Bio: Q1 Earnings SnapshotMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics on Strong Filspari Sales and Favorable Regulatory ProspectsMay 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Travere Therapeutics (TVTX)May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics on Robust Drug Sales and Promising Market ExpansionMay 7, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)May 7, 2024 | msn.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call TranscriptMay 7, 2024 | finance.yahoo.comTravere Therapeutics Inc (TVTX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...May 6, 2024 | finance.yahoo.comTravere Therapeutics Reports Q1 2024 Results: A Mixed Financial Performance Amidst Strategic ...May 6, 2024 | msn.comTVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024See More Headlines Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TVTX CUSIPN/A CIK1438533 Webwww.retrophin.com Phone(888) 969-7879Fax302-645-1280Employees460Year FoundedN/APrice Target and Rating Average Stock Price Target$14.64 High Stock Price Target$27.00 Low Stock Price Target$9.00 Potential Upside/Downside+48.0%Consensus RatingModerate Buy Rating Score (0-4)2.58 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-111,400,000.00 Net Margins-87.94% Pretax Margin-226.71% Return on Equity-238.06% Return on Assets-52.87% Debt Debt-to-Equity Ratio5.10 Current Ratio2.78 Quick Ratio2.75 Sales & Book Value Annual Sales$145.24 million Price / Sales5.18 Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book3.70Miscellaneous Outstanding Shares76,130,000Free Float73,274,000Market Cap$752.93 million OptionableOptionable Beta0.77 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Eric M. Dube Ph.D. (Age 50)President, CEO & Director Comp: $1.4MMr. Christopher Cline C.F.A. (Age 39)Chief Financial Officer Comp: $709.94kMs. Elizabeth E. Reed J.D. (Age 53)Senior VP, General Counsel & Corporate Secretary Comp: $713.63kDr. William E. Rote Ph.D. (Age 61)Senior VP and Head of Research & Development Comp: $748.02kMr. Peter Heerma (Age 52)Chief Commercial Officer Comp: $742.37kMs. Sandra Calvin (Age 58)SVP, Corporate Controller & Chief Accounting Officer Ms. Naomi EichenbaumVice President of Investor RelationsMs. Charlotte SmithSenior Vice President of Public AffairsMs. Angela GiannantonioSenior Vice President of Human ResourcesMr. Casey LoganChief Business OfficerMore ExecutivesKey CompetitorsHarrowNASDAQ:HROWOmerosNASDAQ:OMEREpizymeNASDAQ:EPZMRigel PharmaceuticalsNASDAQ:RIGLACADIA PharmaceuticalsNASDAQ:ACADView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 41,048 shares on 7/26/2024Ownership: 0.348%Assenagon Asset Management S.A.Bought 1,995,419 shares on 7/18/2024Ownership: 2.908%Oak Ridge Investments LLCSold 8,342 shares on 7/17/2024Ownership: 0.076%SG Americas Securities LLCBought 16,884 shares on 7/12/2024Ownership: 0.022%Talbot Financial LLCBought 63,546 shares on 7/11/2024Ownership: 0.083%View All Insider TransactionsView All Institutional Transactions TVTX Stock Analysis - Frequently Asked Questions How have TVTX shares performed this year? Travere Therapeutics' stock was trading at $8.99 at the start of the year. Since then, TVTX stock has increased by 10.0% and is now trading at $9.89. View the best growth stocks for 2024 here. How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:TVTX) announced its earnings results on Monday, May, 6th. The company reported ($1.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by $0.78. Travere Therapeutics's revenue for the quarter was up 34.0% on a year-over-year basis. Who are Travere Therapeutics' major shareholders? Top institutional investors of Travere Therapeutics include Assenagon Asset Management S.A. (2.91%), Bank of New York Mellon Corp (0.35%), Talbot Financial LLC (0.08%) and Oak Ridge Investments LLC (0.08%). Insiders that own company stock include Eric M Dube, Steve Aselage, Peter Heerma, William E Rote, Christopher R Cline, Elizabeth E Reed, Sandra Calvin, Laura Clague, Jula Inrig and Noah L Rosenberg. View institutional ownership trends. How do I buy shares of Travere Therapeutics? Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TVTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.